Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma.
Trending
- High tomato prices blamed on low harvests, rising costs
- Agronomist calls for more awareness on GM, hybrid crops
- RIFAN urges FG to channel farm interventions through associations
- UN human rights council adopts first resolution on neglected tropical diseases
- NAMA urges FG to protect local auto industry
- COREN unveils new strategy to boost engineering regulation
- NCAA warns against reducing Its revenue share
- Malaria vonsortium launches 2026 SMC campaign in Plateau
